25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Affimed NV
Buy, Hold or Sell?

Let's analyze Affimed together

I guess you are interested in Affimed NV. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Affimed NV. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Affimed NV

I send you an email if I find something interesting about Affimed NV.

1. Quick Overview

1.1. Quick analysis of Affimed (30 sec.)










1.2. What can you expect buying and holding a share of Affimed? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$1.94
Expected worth in 1 year
$-2.80
How sure are you?
35.0%

+ What do you gain per year?

Total Gains per Share
$-4.73
Return On Investment
-170.3%

For what price can you sell your share?

Current Price per Share
$2.78
Expected price per share
$2.235 - $4.0413
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Affimed (5 min.)




Live pricePrice per Share (EOD)
$2.78
Intrinsic Value Per Share
$-59.14 - $-16.22
Total Value Per Share
$-57.20 - $-14.28

2.2. Growth of Affimed (5 min.)




Is Affimed growing?

Current yearPrevious yearGrowGrow %
How rich?$30.3m$140.5m-$94.4m-204.8%

How much money is Affimed making?

Current yearPrevious yearGrowGrow %
Making money-$19.6m-$28.8m$9.2m46.8%
Net Profit Margin-8,419.6%-1,162.8%--

How much money comes from the company's main activities?

2.3. Financial Health of Affimed (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Affimed?

Welcome investor! Affimed's management wants to use your money to grow the business. In return you get a share of Affimed.

First you should know what it really means to hold a share of Affimed. And how you can make/lose money.

Speculation

The Price per Share of Affimed is $2.78. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Affimed.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Affimed, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.94. Based on the TTM, the Book Value Change Per Share is $-1.18 per quarter. Based on the YOY, the Book Value Change Per Share is $1.32 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Affimed.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.04-37.5%-1.25-45.1%-1.76-63.5%-1.00-36.1%-0.78-28.0%
Usd Book Value Change Per Share0.000.0%-1.18-42.6%1.3247.5%-0.01-0.5%0.227.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.000.0%-1.18-42.6%1.3247.5%-0.01-0.5%0.227.9%
Usd Price Per Share5.45-2.96-1.16-3.64-3.88-
Price to Earnings Ratio-1.31--0.69--0.20--0.48--0.97-
Price-to-Total Gains Ratio-2.38--0.22-3.44--1.26-
Price to Book Ratio2.82-1.47-0.12-1.48-1.44-
Price-to-Total Gains Ratio-2.38--0.22-3.44--1.26-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.78
Number of shares359
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-1.18-0.01
Usd Total Gains Per Share-1.18-0.01
Gains per Quarter (359 shares)-424.81-5.00
Gains per Year (359 shares)-1,699.24-20.00
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1699-17090-20-30
20-3398-34080-40-50
30-5098-51070-60-70
40-6797-68060-80-90
50-8496-85050-100-110
60-10195-102040-120-130
70-11895-119030-140-150
80-13594-136020-160-170
90-15293-153010-180-190
100-16992-170000-200-210

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%5.035.00.012.5%6.040.01.012.8%
Book Value Change Per Share0.03.01.00.0%2.08.02.016.7%7.011.02.035.0%14.024.02.035.0%15.027.05.031.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.047.00.0%
Total Gains per Share0.03.01.00.0%2.08.02.016.7%7.011.02.035.0%14.024.02.035.0%15.027.05.031.9%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Affimed NV compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share----1.1830%1.321-100%-0.0140%0.219-100%
Book Value Per Share--1.9362.941-34%8.964-78%5.078-62%4.025-52%
Current Ratio--2.7103.045-11%5.353-49%3.484-22%5.234-48%
Debt To Asset Ratio--0.4600.427+8%0.251+84%0.447+3%0.357+29%
Debt To Equity Ratio--0.8520.754+13%0.335+154%0.982-13%0.736+16%
Dividend Per Share----0%-0%-0%-0%
Eps---1.042-1.254+20%-1.764+69%-1.005-4%-0.777-25%
Free Cash Flow Per Share---1.114-1.320+18%-1.974+77%-1.049-6%-0.619-44%
Free Cash Flow To Equity Per Share---1.031-1.313+27%-2.079+102%-0.570-45%-0.143-86%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---16.219--------
Intrinsic Value_10Y_min---59.138--------
Intrinsic Value_1Y_max---2.355--------
Intrinsic Value_1Y_min---6.315--------
Intrinsic Value_3Y_max---6.519--------
Intrinsic Value_3Y_min---18.750--------
Intrinsic Value_5Y_max---10.013--------
Intrinsic Value_5Y_min---30.843--------
Market Cap43592624.000-96%85460360.00046465738.580+84%18204624.760+369%104105706.107-18%84312178.853+1%
Net Profit Margin---100.331-84.196-16%-11.628-88%-20.672-79%-17.097-83%
Operating Margin----58.0010%-11.3580%-15.3310%-14.6880%
Operating Ratio--102.35786.556+18%12.865+696%21.961+366%4551812205.107-100%
Pb Ratio1.436-96%2.8151.469+92%0.123+2196%1.484+90%1.444+95%
Pe Ratio-0.667+49%-1.308-0.693-47%-0.197-85%-0.481-63%-0.969-26%
Price Per Share2.780-96%5.4502.963+84%1.161+369%3.642+50%3.878+41%
Price To Free Cash Flow Ratio-0.624+49%-1.223-0.648-47%-0.174-86%2.060-159%-0.483-60%
Quick Ratio--1.8163.715-51%5.128-65%3.508-48%5.516-67%
Return On Assets---0.291-0.264-9%-0.169-42%-0.142-51%-0.120-59%
Return On Equity---0.538-0.467-13%-0.228-58%-0.272-50%-0.199-63%
Total Gains Per Share----1.1830%1.321-100%-0.0140%0.219-100%
Usd Book Value--30353569.40046118894.525-34%140559944.250-78%93467672.045-68%70039693.295-57%
Usd Book Value Change Per Share----1.1830%1.321-100%-0.0140%0.219-100%
Usd Book Value Per Share--1.9362.941-34%8.964-78%5.078-62%4.025-52%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---1.042-1.254+20%-1.764+69%-1.005-4%-0.777-25%
Usd Free Cash Flow---17471748.800-20702510.675+18%-30961401.900+77%-16976761.725-3%-9964356.738-43%
Usd Free Cash Flow Per Share---1.114-1.320+18%-1.974+77%-1.049-6%-0.619-44%
Usd Free Cash Flow To Equity Per Share---1.031-1.313+27%-2.079+102%-0.570-45%-0.143-86%
Usd Market Cap43592624.000-96%85460360.00046465738.580+84%18204624.760+369%104105706.107-18%84312178.853+1%
Usd Price Per Share2.780-96%5.4502.963+84%1.161+369%3.642+50%3.878+41%
Usd Profit---16333252.100-19670516.800+20%-28882879.025+77%-19096458.645+17%-12418520.098-24%
Usd Revenue--162793.400640866.875-75%7617991.150-98%6247091.015-97%4628723.770-96%
Usd Total Gains Per Share----1.1830%1.321-100%-0.0140%0.219-100%
 EOD+2 -5MRQTTM+13 -14YOY+13 -185Y+5 -2210Y+6 -25

3.3 Fundamental Score

Let's check the fundamental score of Affimed NV based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.667
Price to Book Ratio (EOD)Between0-11.436
Net Profit Margin (MRQ)Greater than0-100.331
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.816
Current Ratio (MRQ)Greater than12.710
Debt to Asset Ratio (MRQ)Less than10.460
Debt to Equity Ratio (MRQ)Less than10.852
Return on Equity (MRQ)Greater than0.15-0.538
Return on Assets (MRQ)Greater than0.05-0.291
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Affimed NV based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose2.850
Total1/1 (100.0%)

4. In-depth Analysis

4.1 About Affimed NV

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.

Fundamental data was last updated by Penke on 2024-11-14 09:24:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Affimed earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Affimed to the Biotechnology industry mean.
  • A Net Profit Margin of -10,033.1% means that $-100.33 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Affimed NV:

  • The MRQ is -10,033.1%. The company is making a huge loss. -2
  • The TTM is -8,419.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-10,033.1%TTM-8,419.6%-1,613.5%
TTM-8,419.6%YOY-1,162.8%-7,256.8%
TTM-8,419.6%5Y-2,067.2%-6,352.4%
5Y-2,067.2%10Y-1,709.7%-357.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10,033.1%-112.2%-9,920.9%
TTM-8,419.6%-221.4%-8,198.2%
YOY-1,162.8%-210.0%-952.8%
5Y-2,067.2%-342.2%-1,725.0%
10Y-1,709.7%-464.5%-1,245.2%
4.3.1.2. Return on Assets

Shows how efficient Affimed is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Affimed to the Biotechnology industry mean.
  • -29.1% Return on Assets means that Affimed generated $-0.29 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Affimed NV:

  • The MRQ is -29.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -26.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-29.1%TTM-26.4%-2.7%
TTM-26.4%YOY-16.9%-9.4%
TTM-26.4%5Y-14.2%-12.2%
5Y-14.2%10Y-12.0%-2.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-29.1%-11.3%-17.8%
TTM-26.4%-11.7%-14.7%
YOY-16.9%-11.3%-5.6%
5Y-14.2%-12.7%-1.5%
10Y-12.0%-14.1%+2.1%
4.3.1.3. Return on Equity

Shows how efficient Affimed is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Affimed to the Biotechnology industry mean.
  • -53.8% Return on Equity means Affimed generated $-0.54 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Affimed NV:

  • The MRQ is -53.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -46.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-53.8%TTM-46.7%-7.1%
TTM-46.7%YOY-22.8%-23.9%
TTM-46.7%5Y-27.2%-19.5%
5Y-27.2%10Y-19.9%-7.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-53.8%-14.2%-39.6%
TTM-46.7%-15.9%-30.8%
YOY-22.8%-14.3%-8.5%
5Y-27.2%-18.5%-8.7%
10Y-19.9%-19.3%-0.6%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Affimed NV.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Affimed is operating .

  • Measures how much profit Affimed makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Affimed to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Affimed NV:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-5,800.1%+5,800.1%
TTM-5,800.1%YOY-1,135.8%-4,664.2%
TTM-5,800.1%5Y-1,533.1%-4,267.0%
5Y-1,533.1%10Y-1,468.8%-64.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--222.9%+222.9%
TTM-5,800.1%-310.7%-5,489.4%
YOY-1,135.8%-223.5%-912.3%
5Y-1,533.1%-387.1%-1,146.0%
10Y-1,468.8%-498.5%-970.3%
4.3.2.2. Operating Ratio

Measures how efficient Affimed is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 102.36 means that the operating costs are $102.36 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Affimed NV:

  • The MRQ is 102.357. The company is inefficient in keeping operating costs low. -1
  • The TTM is 86.556. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ102.357TTM86.556+15.801
TTM86.556YOY12.865+73.691
TTM86.5565Y21.961+64.595
5Y21.96110Y4,551,812,205.107-4,551,812,183.146
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ102.3572.465+99.892
TTM86.5563.253+83.303
YOY12.8653.298+9.567
5Y21.9614.788+17.173
10Y4,551,812,205.1076.494+4,551,812,198.613
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Affimed NV.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Affimed is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.71 means the company has $2.71 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Affimed NV:

  • The MRQ is 2.710. The company is able to pay all its short-term debts. +1
  • The TTM is 3.045. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ2.710TTM3.045-0.334
TTM3.045YOY5.353-2.309
TTM3.0455Y3.484-0.440
5Y3.48410Y5.234-1.749
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.7103.637-0.927
TTM3.0453.890-0.845
YOY5.3534.666+0.687
5Y3.4845.953-2.469
10Y5.2346.277-1.043
4.4.3.2. Quick Ratio

Measures if Affimed is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Affimed to the Biotechnology industry mean.
  • A Quick Ratio of 1.82 means the company can pay off $1.82 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Affimed NV:

  • The MRQ is 1.816. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.715. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.816TTM3.715-1.899
TTM3.715YOY5.128-1.412
TTM3.7155Y3.508+0.207
5Y3.50810Y5.516-2.008
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8163.086-1.270
TTM3.7153.451+0.264
YOY5.1284.456+0.672
5Y3.5085.931-2.423
10Y5.5166.436-0.920
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Affimed NV.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Affimed assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Affimed to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.46 means that Affimed assets are financed with 46.0% credit (debt) and the remaining percentage (100% - 46.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Affimed NV:

  • The MRQ is 0.460. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.427. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.460TTM0.427+0.033
TTM0.427YOY0.251+0.177
TTM0.4275Y0.447-0.020
5Y0.44710Y0.357+0.090
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4600.350+0.110
TTM0.4270.344+0.083
YOY0.2510.310-0.059
5Y0.4470.365+0.082
10Y0.3570.382-0.025
4.5.4.2. Debt to Equity Ratio

Measures if Affimed is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Affimed to the Biotechnology industry mean.
  • A Debt to Equity ratio of 85.2% means that company has $0.85 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Affimed NV:

  • The MRQ is 0.852. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.754. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.852TTM0.754+0.098
TTM0.754YOY0.335+0.419
TTM0.7545Y0.982-0.228
5Y0.98210Y0.736+0.246
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8520.394+0.458
TTM0.7540.432+0.322
YOY0.3350.380-0.045
5Y0.9820.451+0.531
10Y0.7360.490+0.246
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Affimed generates.

  • Above 15 is considered overpriced but always compare Affimed to the Biotechnology industry mean.
  • A PE ratio of -1.31 means the investor is paying $-1.31 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Affimed NV:

  • The EOD is -0.667. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.308. Based on the earnings, the company is expensive. -2
  • The TTM is -0.693. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.667MRQ-1.308+0.641
MRQ-1.308TTM-0.693-0.615
TTM-0.693YOY-0.197-0.496
TTM-0.6935Y-0.481-0.212
5Y-0.48110Y-0.969+0.488
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.667-2.303+1.636
MRQ-1.308-2.403+1.095
TTM-0.693-3.148+2.455
YOY-0.197-3.251+3.054
5Y-0.481-6.084+5.603
10Y-0.969-6.764+5.795
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Affimed NV:

  • The EOD is -0.624. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.223. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.648. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.624MRQ-1.223+0.599
MRQ-1.223TTM-0.648-0.575
TTM-0.648YOY-0.174-0.474
TTM-0.6485Y2.060-2.708
5Y2.06010Y-0.483+2.544
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.624-3.042+2.418
MRQ-1.223-3.234+2.011
TTM-0.648-3.719+3.071
YOY-0.174-4.557+4.383
5Y2.060-8.332+10.392
10Y-0.483-9.276+8.793
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Affimed is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.82 means the investor is paying $2.82 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Affimed NV:

  • The EOD is 1.436. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.815. Based on the equity, the company is underpriced. +1
  • The TTM is 1.469. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.436MRQ2.815-1.379
MRQ2.815TTM1.469+1.347
TTM1.469YOY0.123+1.346
TTM1.4695Y1.484-0.016
5Y1.48410Y1.444+0.040
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.4361.943-0.507
MRQ2.8152.051+0.764
TTM1.4692.356-0.887
YOY0.1232.454-2.331
5Y1.4843.714-2.230
10Y1.4444.378-2.934
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Affimed NV.

4.8.1. Institutions holding Affimed NV

Institutions are holding 36.656% of the shares of Affimed NV.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-06-30683 Capital Management LLC4.14520.2677650000-19998-2.9848
2024-06-30Morgan Stanley - Brokerage Accounts3.56870.0001559606305706120.4041
2024-06-30NEA Management Company, LLC2.82290.181544264900
2024-06-30Millennium Management LLC2.37740.00093727883508061595.8784
2024-06-30Point72 Asset Management, L.P.2.09010.0047327748-94834-22.4416
2024-06-30Eversept Partners, LLC1.06160.062116646000
2024-06-30Verition Fund Managegment, LLC0.84240.00391320875045361.8039
2024-06-30Vanguard Group Inc0.8262012956000
2024-06-30BNP Paribas Arbitrage, SA0.54760.0004858661328218.2988
2024-06-30Intellectus Partners, LLC0.53640.1251841114089794.6383
2024-06-30State Street Corp0.351305508810381.9204
2024-06-30Walleye Trading Advisors, LLC0.15370.000224106241060
2024-06-30Commonwealth Equity Services Inc0.13770.00022159000
2024-09-30abrdn PLC0.1330.00012086200
2024-06-30Jump Financial LLC0.11310.001917733177330
2024-06-30BlackRock Inc0.1038016283-662-3.9068
2024-06-30Clayton Financial Group LLC0.09570.03441500000
2024-06-30FMR Inc0.08680136106124.7084
2024-06-30Geode Capital Management, LLC0.086701359400
2024-06-30EWA, LLC0.07920.026812421-1435-10.3565
Total 20.15950.713161162+687704+21.8%

4.9.2. Funds holding Affimed NV

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Vanguard Explorer Inv0.48250.00117566700
2024-09-30Vanguard VIF Small Co Gr0.34370.01165389300
2024-09-30abrdn Life Sciences Investors0.1330.01522086200
2024-09-30DFA US Targeted Value I0.11190.00041754514054402.5781
2024-09-30Fidelity Nasdaq Composite Index0.04690.0001735100
2024-08-31Fidelity VIP Disciplined Small Cap Init0.02850.0043446800
2024-09-30JNL/DFA US Small Cap A0.00370.000357500
2024-08-31Guggenheim Active Allocation Fund0.000406900
2024-05-31Nationwide Multi-Cap Portfolio R60.000406600
Total 1.1510.033180496+14054+7.8%
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in EUR. All numbers in thousands.

Summary
Total Assets53,174
Total Liabilities24,460
Total Stockholder Equity28,714
 As reported
Total Liabilities 24,460
Total Stockholder Equity+ 28,714
Total Assets = 53,174

Assets

Total Assets53,174
Total Current Assets45,187
Long-term Assets7,987
Total Current Assets
Cash And Cash Equivalents 10,764
Short-term Investments 24,561
Net Receivables 5,717
Other Current Assets 4,145
Total Current Assets  (as reported)45,187
Total Current Assets  (calculated)45,187
+/-0
Long-term Assets
Property Plant Equipment 7,969
Intangible Assets 18
Long-term Assets  (as reported)7,987
Long-term Assets  (calculated)7,987
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities16,672
Long-term Liabilities7,788
Total Stockholder Equity28,714
Total Current Liabilities
Short Long Term Debt 5,833
Accounts payable 9,171
Total Current Liabilities  (as reported)16,672
Total Current Liabilities  (calculated)15,004
+/- 1,668
Long-term Liabilities
Long term Debt 3,603
Capital Lease Obligations Min Short Term Debt5,079
Long-term Liabilities  (as reported)7,788
Long-term Liabilities  (calculated)8,682
+/- 894
Total Stockholder Equity
Total Stockholder Equity (as reported)28,714
Total Stockholder Equity (calculated)0
+/- 28,714
Other
Capital Stock1,568
Common Stock Shares Outstanding 15,681
Net Invested Capital 38,150
Net Working Capital 28,515
Property Plant and Equipment Gross 7,969



5.2. Balance Sheets Structured

Currency in EUR. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-31
> Total Assets 
9,482
0
0
0
6,500
7,047
4,510
47,860
41,909
39,290
69,824
63,131
79,322
70,600
61,642
53,235
48,739
57,044
53,219
45,356
43,158
66,589
59,515
49,069
116,174
110,339
99,117
85,550
112,359
112,359
101,148
107,938
175,725
175,725
248,023
220,335
225,135
193,251
260,905
236,399
200,512
134,711
134,711
120,464
70,553
53,174
53,174
53,17453,17470,553120,464134,711134,711200,512236,399260,905193,251225,135220,335248,023175,725175,725107,938101,148112,359112,35985,55099,117110,339116,17449,06959,51566,58943,15845,35653,21957,04448,73953,23561,64270,60079,32263,13169,82439,29041,90947,8604,5107,0476,5000009,482
   > Total Current Assets 
0
0
0
0
5,292
5,849
3,442
46,665
40,863
38,291
68,861
62,111
78,335
69,595
60,680
52,326
47,862
56,161
52,154
44,180
41,980
58,226
50,677
40,146
110,879
104,325
92,487
79,530
105,914
105,914
95,069
101,392
150,799
150,799
227,186
203,271
206,394
180,930
254,791
230,550
196,070
130,836
130,836
106,829
62,157
45,187
45,187
45,18745,18762,157106,829130,836130,836196,070230,550254,791180,930206,394203,271227,186150,799150,799101,39295,069105,914105,91479,53092,487104,325110,87940,14650,67758,22641,98044,18052,15456,16147,86252,32660,68069,59578,33562,11168,86138,29140,86346,6653,4425,8495,2920000
       Cash And Cash Equivalents 
6,464
0
0
0
4,151
5,044
1,800
45,546
39,725
37,033
66,319
60,425
76,740
49,181
40,603
35,693
35,407
49,007
44,486
33,343
39,837
55,339
47,412
37,076
94,829
63,089
63,987
59,995
95,234
95,234
84,584
89,656
146,854
146,854
222,676
198,742
197,630
169,850
237,232
222,895
190,286
120,056
120,056
62,817
14,348
10,764
10,764
10,76410,76414,34862,817120,056120,056190,286222,895237,232169,850197,630198,742222,676146,854146,85489,65684,58495,23495,23459,99563,98763,08994,82937,07647,41255,33939,83733,34344,48649,00735,40735,69340,60349,18176,74060,42566,31937,03339,72545,5461,8005,0444,1510006,464
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
17,567
18,015
13,440
9,487
4,676
4,381
8,470
0
0
0
0
13,974
32,043
23,726
16,530
8,902
8,902
8,037
7,687
0
0
0
0
0
0
0
0
0
0
0
34,659
35,027
24,561
24,561
24,56124,56135,02734,659000000000007,6878,0378,9028,90216,53023,72632,04313,97400008,4704,3814,6769,48713,44018,01517,5670000000000000
       Net Receivables 
0
0
0
0
1,001
667
1,469
932
939
1,057
2,320
1,447
915
1,923
1,147
2,337
2,255
2,275
2,524
1,583
1,102
1,812
1,024
1,443
1,429
8,298
1,471
1,184
1,482
1,482
2,027
2,552
2,439
2,439
3,763
3,759
4,809
4,547
5,524
1,691
2,697
2,154
2,154
2,446
6,038
5,717
5,717
5,7175,7176,0382,4462,1542,1542,6971,6915,5244,5474,8093,7593,7632,4392,4392,5522,0271,4821,4821,1841,4718,2981,4291,4431,0241,8121,1021,5832,5242,2752,2552,3371,1471,9239151,4472,3201,0579399321,4696671,0010000
       Other Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
452
682
682
603
516
12
513
502
800
813
1,974
1,307
387
570
2,973
1,491
8,902
0
0
1,087
1,260
1,260
135
78
3,534
6,048
7,407
760
2,459
7,932
7,932
6,098
6,044
4,145
4,145
4,1454,1456,0446,0987,9327,9322,4597607,4076,0483,534781351,2601,2601,087008,9021,4912,9735703871,3071,97481380050251312516603682682452000000000000
   > Long-term Assets 
0
0
0
0
1,208
1,198
1,068
1,195
1,046
999
963
1,020
987
1,005
962
909
877
883
1,065
1,176
1,178
8,363
8,838
8,923
5,295
6,014
6,630
6,020
6,445
6,445
6,079
6,546
24,926
24,926
20,837
17,064
18,741
12,321
6,114
5,849
4,442
3,875
3,875
13,635
8,396
7,987
7,987
7,9877,9878,39613,6353,8753,8754,4425,8496,11412,32118,74117,06420,83724,92624,9266,5466,0796,4456,4456,0206,6306,0145,2958,9238,8388,3631,1781,1761,0658838779099621,0059871,0209639991,0461,1951,0681,1981,2080000
       Property Plant Equipment 
1,615
0
0
0
1,034
968
907
1,044
974
929
899
959
915
932
897
845
822
828
1,004
1,120
1,113
1,168
1,230
1,271
1,414
2,009
2,613
2,577
3,115
3,115
2,773
3,389
3,166
3,166
4,483
4,226
4,786
4,567
4,561
4,294
4,384
3,829
3,829
13,594
8,374
7,969
7,969
7,9697,9698,37413,5943,8293,8294,3844,2944,5614,5674,7864,2264,4833,1663,1663,3892,7733,1153,1152,5772,6132,0091,4141,2711,2301,1681,1131,1201,0048288228458979329159598999299741,0449079681,0340001,615
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,771
8,771
13,631
13,149
3,898
3,849
3,294
3,193
3,274
3,203
3,064
20,042
18,789
14,693
11,204
12,348
6,174
0
0
0
0
0
0
0
0
0
0000000006,17412,34811,20414,69318,78920,0423,0643,2033,2743,1933,2943,8493,89813,14913,6318,7718,771000000000000000000000
       Intangible Assets 
343
0
0
0
158
145
116
96
72
70
64
61
72
73
65
64
55
55
61
56
65
65
72
63
56
107
168
149
137
137
103
93
1,718
1,718
0
0
1,607
0
0
0
58
0
0
0
25
18
18
181825000580001,607001,7181,71893103137137149168107566372656556615555646573726164707296116145158000343
       Long-term Assets Other 
0
0
0
0
0
100
100
0
-100
0
-100
-100
0
0
-100
0
-100
-100
-100
0
0
-30
-36
11
0
6,014
6,630
6,020
6,445
0
0
0
0
0
1,661
1,634
0
1,580
1,553
0
0
0
0
0
0
0
0
000000001,5531,58001,6341,661000006,4456,0206,6306,014011-36-3000-100-100-1000-10000-100-1000-100010010000000
> Total Liabilities 
105,904
0
0
0
105,723
121,916
106,025
10,078
10,114
8,637
9,472
9,409
12,048
10,841
9,082
10,036
9,988
9,452
13,085
11,549
11,579
12,327
12,334
13,221
76,045
67,684
66,272
63,317
73,692
73,692
60,646
60,922
103,732
103,732
97,144
86,478
89,184
75,831
68,085
55,296
47,597
35,785
35,785
44,044
29,890
24,460
24,460
24,46024,46029,89044,04435,78535,78547,59755,29668,08575,83189,18486,47897,144103,732103,73260,92260,64673,69273,69263,31766,27267,68476,04513,22112,33412,32711,57911,54913,0859,4529,98810,0369,08210,84112,0489,4099,4728,63710,11410,078106,025121,916105,723000105,904
   > Total Current Liabilities 
2,722
0
0
0
14,940
22,389
15,490
6,408
6,219
4,129
5,135
5,968
8,944
8,332
6,954
8,351
6,371
6,152
7,801
6,867
7,493
8,845
9,465
10,977
36,843
32,937
26,565
29,153
35,181
35,181
32,491
45,180
67,027
67,027
67,157
66,291
64,547
57,795
52,008
40,828
34,651
25,888
25,888
28,887
20,315
16,672
16,672
16,67216,67220,31528,88725,88825,88834,65140,82852,00857,79564,54766,29167,15767,02767,02745,18032,49135,18135,18129,15326,56532,93736,84310,9779,4658,8457,4936,8677,8016,1526,3718,3516,9548,3328,9445,9685,1354,1296,2196,40815,49022,38914,9400002,722
       Short-term Debt 
0
0
0
0
4,800
4,976
5,153
131
3,759
0
0
932
1,472
1,920
2,149
1,959
973
1,389
1,750
2,500
3,083
3,083
3,083
3,083
3,083
3,417
3,929
3,297
2,637
2,637
1,490
1,849
584
584
616
760
1,263
2,631
4,111
5,498
6,326
6,123
6,123
6,538
6,805
6,882
0
06,8826,8056,5386,1236,1236,3265,4984,1112,6311,2637606165845841,8491,4902,6372,6373,2973,9293,4173,0833,0833,0833,0833,0832,5001,7501,3899731,9592,1491,9201,472932003,7591315,1534,9764,8000000
       Short Long Term Debt 
0
0
0
0
82,745
22,352
0
0
3,895
0
0
0
1,472
0
0
0
973
4,689
7,034
2,500
3,083
3,793
3,588
5,538
10,598
3,083
3,552
2,960
2,105
1,401
1,039
1,070
92
92
93
94
580
2,039
3,498
4,957
5,930
5,930
5,923
5,898
5,833
5,833
5,833
5,8335,8335,8335,8985,9235,9305,9304,9573,4982,039580949392921,0701,0391,4012,1052,9603,5523,08310,5985,5383,5883,7933,0832,5007,0344,6899730001,4720003,8950022,35282,7450000
       Accounts payable 
2,300
0
0
0
3,862
4,012
3,404
4,996
3,759
3,113
4,563
4,879
4,444
4,711
4,698
6,327
5,323
4,536
5,793
4,334
4,180
5,307
5,926
7,253
9,425
6,289
7,541
7,633
10,674
10,674
6,606
8,123
7,986
11,394
15,838
13,716
18,860
13,537
12,760
15,078
19,077
15,810
15,810
21,713
12,891
9,171
9,171
9,1719,17112,89121,71315,81015,81019,07715,07812,76013,53718,86013,71615,83811,3947,9868,1236,60610,67410,6747,6337,5416,2899,4257,2535,9265,3074,1804,3345,7934,5365,3236,3274,6984,7114,4444,8794,5633,1133,7594,9963,4044,0123,8620002,300
       Other Current Liabilities 
422
0
0
0
6,196
11,242
4,875
1,618
3,759
1,091
638
35
4,049
1,937
118
73
941
243
294
39
1,239
560
531
1,151
86,894
65,112
1,440
1,131
517
517
484
479
58,457
50,920
50,703
51,815
46,199
41,627
35,137
20,252
0
0
3,955
636
0
0
0
0006363,9550020,25235,13741,62746,19951,81550,70350,92058,4574794845175171,1311,44065,11286,8941,1515315601,23939294243941731181,9374,049356381,0913,7591,6184,87511,2426,196000422
   > Long-term Liabilities 
0
0
0
0
90,783
99,527
90,535
3,670
3,895
4,508
4,337
3,441
3,104
2,509
2,128
1,685
3,617
3,300
5,284
4,682
4,086
3,482
2,869
2,244
39,202
34,747
39,707
34,164
38,511
38,511
28,155
15,742
36,705
36,705
29,987
20,187
24,637
18,036
16,077
14,468
12,946
9,897
9,897
15,157
9,575
7,788
7,788
7,7887,7889,57515,1579,8979,89712,94614,46816,07718,03624,63720,18729,98736,70536,70515,74228,15538,51138,51134,16439,70734,74739,2022,2442,8693,4824,0864,6825,2843,3003,6171,6852,1282,5093,1043,4414,3374,5083,8953,67090,53599,52790,7830000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,482
5,065
1,259
569
492
550
409
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000004095504925691,2595,0653,48200000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
-4,800
-4,976
-5,153
-131
-3,759
0
0
-932
-1,472
-1,920
-2,149
-1,959
-973
-1,389
-1,750
-2,500
-3,083
-3,083
-3,083
-3,083
-3,083
-2,781
-3,306
-2,768
-1,833
-1,960
-944
-738
390
648
508
220
-212
-1,751
-3,181
-4,754
-5,754
-5,675
-5,800
976
394
-1,610
5,079
5,079-1,610394976-5,800-5,675-5,754-4,754-3,181-1,751-212220508648390-738-944-1,960-1,833-2,768-3,306-2,781-3,083-3,083-3,083-3,083-3,083-2,500-1,750-1,389-973-1,959-2,149-1,920-1,472-93200-3,759-131-5,153-4,976-4,8000000
> Total Stockholder Equity
0
0
0
0
-99,223
-114,869
-101,515
37,782
31,795
30,653
60,352
53,722
67,274
59,759
52,560
43,199
38,751
47,592
40,134
33,807
31,579
54,262
47,181
35,848
40,129
42,655
32,845
22,233
38,667
38,667
40,502
47,016
71,993
71,993
150,879
133,857
135,951
117,420
192,820
181,103
152,915
98,926
98,926
76,420
40,663
28,714
28,714
28,71428,71440,66376,42098,92698,926152,915181,103192,820117,420135,951133,857150,87971,99371,99347,01640,50238,66738,66722,23332,84542,65540,12935,84847,18154,26231,57933,80740,13447,59238,75143,19952,56059,75967,27453,72260,35230,65331,79537,782-101,515-114,869-99,2230000
   Retained Earnings -570,754-570,754-555,303-515,923-491,568-491,568-430,190-392,826-372,290-350,062-333,397-310,309-293,214-275,874-275,874-261,001-255,035-234,508-234,508-221,516-210,632-200,292-202,144-210,904-198,884-190,870-182,667-176,246-168,146-160,199-152,444-147,022-136,727-128,690-120,228-113,949-106,657-101,473-99,989-94,689-102,022-115,376-99,7300000
   Accumulated Other Comprehensive Income 
0
0
0
0
469
469
469
132,231
131,544
131,886
166,710
167,372
187,169
188,116
188,954
189,888
190,862
207,352
207,841
209,606
213,778
244,508
245,441
246,128
241,649
242,323
242,853
243,125
272,413
272,413
294,692
307,134
346,884
346,884
442,896
442,968
468,114
466,248
563,617
572,436
581,612
589,001
589,001
590,850
594,443
597,900
0
0597,900594,443590,850589,001589,001581,612572,436563,617466,248468,114442,968442,896346,884346,884307,134294,692272,413272,413243,125242,853242,323241,649246,128245,441244,508213,778209,606207,841207,352190,862189,888188,954188,116187,169167,372166,710131,886131,544132,2314694694690000
   Capital Surplus 00000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000-340-34000-33



5.3. Balance Sheets

Currency in EUR. All numbers in thousands.




5.4. Cash Flows

Currency in EUR. All numbers in thousands.




5.5. Income Statements

Currency in EUR. All numbers in thousands.